PE20010636A1 - Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica - Google Patents

Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica

Info

Publication number
PE20010636A1
PE20010636A1 PE2000000842A PE0008422000A PE20010636A1 PE 20010636 A1 PE20010636 A1 PE 20010636A1 PE 2000000842 A PE2000000842 A PE 2000000842A PE 0008422000 A PE0008422000 A PE 0008422000A PE 20010636 A1 PE20010636 A1 PE 20010636A1
Authority
PE
Peru
Prior art keywords
chor
ch2o
fatty acids
ch2or
formulation
Prior art date
Application number
PE2000000842A
Other languages
English (en)
Inventor
Tomas Andrysek
Alexandr Jegerov
Ales Vrana
Milan Stuchlik
Josef Stuchlik
Vladimir Matha
Original Assignee
Ivax Cr A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10859192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Cr A S filed Critical Ivax Cr A S
Publication of PE20010636A1 publication Critical patent/PE20010636A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

SE REFIERE A UN METODO PARA INCREMENTAR LA VISCOSIDAD DE UNA FORMULACION DE ADMINISTRACION ORAL O TOPICA LA CUAL COMPRENDE LOS PASOS DE COMBINAR: a)DE 0,1% A 30% DE UN AGENTE ACTIVO HIDROFOBICO TAL COMO TAXANOS (DOCATAXEL, PACLITAXEL), CICLOSPORINAS; b)DE 5% A 50% DE ESTERES DE POLIGLICEROL DE ACIDOS GRASOS DE FORMULA CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]nCH2-CHOR-CH2OR; n ES 4-13; R ES H, CO.R; R` ES ALQUILO C8-C22; R NO ES H; c)DE 5% A 50% DE ESTERES DE POLIGLICEROL DE ACIDOS GRASOS Y ACIDOS GRASOS INSATURADOS DE FORMULA CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]nCH2-CHOR-CH2OR; n ES 0-10; R ES H, CO.R"; R" ES ALQUILO C8-C22, AL MENOS UN R NO ES H; d)DE 5% A 50% DE ESTERES DE GLICEROL MACROGOL TRIGLICERIDO, GLICERIDOS PARCIALES O ACIDOS GRASOS O ESTERES MACROGOL DE ACIDOS GRASOS (ACEITE DE CASTOR HALOGENADO, LA CANTIDAD DE OXIDO DE ETILENO PARA LA SINTESIS DE ESTAS SUSTANCIAS OSCILA ENTRE 50 MOL A 150 MOL, SIENDO LA PROPORCION DE LOS COMPONENTES b Y d DE 0,1:1 A 10:1; DE a:c Y a:e ES DE 0,001:1 A 10:1, SE CARACTERIZA POR LA PREVIA DILUCION EN AGUA 1.1 POR VOLUMEN, LA VISCOSIDAD DE LA FORMULACION SE INCREMENTA EN AL MENOS 5 VECES EN COMPARACION CON LA FORMULACION NO DILUIDA; LA FORMULACION CREA UNA DISPERSION DE PARTICULAS DE GEL POLIMORFO CON UNA DIMENSION DE 0,2µm A 500µm
PE2000000842A 1999-08-17 2000-08-17 Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica PE20010636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9919288A GB2355656B (en) 1999-08-17 1999-08-17 Pharmaceutical compositions for oral and topical administration

Publications (1)

Publication Number Publication Date
PE20010636A1 true PE20010636A1 (es) 2001-06-02

Family

ID=10859192

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000842A PE20010636A1 (es) 1999-08-17 2000-08-17 Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica

Country Status (40)

Country Link
US (1) US20070190132A1 (es)
EP (2) EP1334717B1 (es)
JP (2) JP2003507343A (es)
KR (2) KR100828748B1 (es)
CN (2) CN101406453A (es)
AR (2) AR025324A1 (es)
AT (2) ATE288766T1 (es)
AU (1) AU777740B2 (es)
BR (1) BR0013385A (es)
CA (2) CA2452118A1 (es)
CO (1) CO5380014A1 (es)
CY (1) CY1105318T1 (es)
CZ (2) CZ296591B6 (es)
DE (2) DE60018081T2 (es)
DK (2) DK1210119T3 (es)
EE (2) EE04955B1 (es)
EG (1) EG23994A (es)
ES (2) ES2237443T3 (es)
GB (1) GB2355656B (es)
HK (1) HK1049629A1 (es)
HR (1) HRP20020154B1 (es)
HU (1) HUP0203236A3 (es)
IL (4) IL158108A0 (es)
JO (1) JO2324B1 (es)
MX (1) MXPA02001631A (es)
NO (2) NO20020760L (es)
NZ (1) NZ517271A (es)
PE (1) PE20010636A1 (es)
PL (1) PL192769B1 (es)
PT (2) PT1210119E (es)
RU (2) RU2279894C2 (es)
SA (1) SA00210487B1 (es)
SG (1) SG143019A1 (es)
SI (1) SI1210119T1 (es)
SK (2) SK286083B6 (es)
TN (1) TNSN00173A1 (es)
UA (2) UA72539C2 (es)
UY (1) UY26303A1 (es)
WO (1) WO2001012229A1 (es)
ZA (2) ZA200308221B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
FR2826261B1 (fr) * 2001-06-26 2005-03-25 Lmd Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
EP1935407A1 (en) * 2002-12-03 2008-06-25 Elan Pharma International Limited Low viscosity liquid dosage forms
CN100337620C (zh) * 2002-12-04 2007-09-19 日清药业股份有限公司 含有辅酶q10的水溶性组合物
JP4518042B2 (ja) * 2002-12-04 2010-08-04 日油株式会社 コエンザイムq10を含有する水溶性組成物の製造方法
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
EP1806125B1 (en) * 2004-10-20 2011-08-03 Kao Corporation Liquid compositions for oral cavity
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
BRPI0921654A2 (pt) * 2008-11-28 2016-02-10 Advance Holdings Ltd formulação farmacêutica
DK2405892T3 (da) * 2009-03-12 2013-04-08 Advance Holdings Ltd Farmaceutisk formulering omfattende ketoprofen og en polyoxyalkylenester af en hydroxy-fedtsyre
KR101100933B1 (ko) * 2009-04-23 2012-01-02 한국기술교육대학교 산학협력단 솔더 볼 제거 장치
JP6763939B2 (ja) 2015-03-27 2020-09-30 アーチ・パーソナル・ケア・プロダクツ・エルピー パーソナルケア製品のための粘度増強組成物
CN112426403B (zh) * 2020-12-09 2021-09-17 南京天纵易康生物科技股份有限公司 一种口腔溃疡凝胶及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TR199902199T2 (xx) * 1997-03-12 2002-06-21 Abbott Laboratories Siklosporin tatbiki i�in hidrofilik ikili sistemler.
JP2001515491A (ja) * 1997-03-12 2001-09-18 アボツト・ラボラトリーズ 親油性化合物の投与のための親油性二成分系
PL191780B1 (pl) * 1997-07-29 2006-07-31 Upjohn Co Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration

Also Published As

Publication number Publication date
GB9919288D0 (en) 1999-10-20
DK1334717T3 (da) 2008-11-24
HRP20020154A2 (en) 2003-12-31
IL148200A (en) 2007-12-03
EE04954B1 (et) 2008-02-15
ES2311077T3 (es) 2009-02-01
ZA200201315B (en) 2004-06-30
MXPA02001631A (es) 2003-07-14
HUP0203236A2 (hu) 2003-01-28
IL148200A0 (en) 2002-09-12
EP1210119A1 (en) 2002-06-05
KR20050095651A (ko) 2005-09-29
WO2001012229A1 (en) 2001-02-22
CA2452118A1 (en) 2001-02-22
IL158108A (en) 2010-04-15
PT1210119E (pt) 2005-05-31
SK2482002A3 (en) 2002-12-03
ZA200308221B (en) 2004-09-29
CZ296591B6 (cs) 2006-04-12
EE200200075A (et) 2003-04-15
ES2237443T3 (es) 2005-08-01
RU2279895C2 (ru) 2006-07-20
PL353445A1 (en) 2003-11-17
AR025324A1 (es) 2002-11-20
TNSN00173A1 (en) 2005-11-10
GB2355656A (en) 2001-05-02
SI1210119T1 (en) 2005-06-30
CO5380014A1 (es) 2004-03-31
CN1382061A (zh) 2002-11-27
DE60322454D1 (de) 2008-09-11
EE200300371A (et) 2003-10-15
AR043106A2 (es) 2005-07-20
HUP0203236A3 (en) 2004-06-28
NO20020760L (no) 2002-04-16
PT1334717E (pt) 2008-10-09
CN101406453A (zh) 2009-04-15
JP2004238399A (ja) 2004-08-26
JO2324B1 (en) 2005-09-12
NO20034778D0 (no) 2003-10-24
SK286083B6 (sk) 2008-03-05
US20070190132A1 (en) 2007-08-16
EG23994A (en) 2008-03-10
JP2003507343A (ja) 2003-02-25
EP1334717A2 (en) 2003-08-13
CZ296170B6 (cs) 2006-01-11
GB2355656B (en) 2004-04-07
DK1210119T3 (da) 2005-06-20
HRP20020154B1 (en) 2006-07-31
HK1049629A1 (zh) 2003-05-23
KR100828747B1 (ko) 2008-05-09
NO20034778L (no) 2002-04-16
EP1334717A3 (en) 2004-01-02
RU2003133451A (ru) 2005-04-20
SG143019A1 (en) 2008-06-27
AU777740B2 (en) 2004-10-28
NZ517271A (en) 2004-02-27
CZ2002575A3 (cs) 2003-05-14
BR0013385A (pt) 2002-05-07
ATE402691T1 (de) 2008-08-15
NO20020760D0 (no) 2002-02-15
UA75926C2 (en) 2006-06-15
PL192769B1 (pl) 2006-12-29
EP1334717B1 (en) 2008-07-30
AU6461300A (en) 2001-03-13
ATE288766T1 (de) 2005-02-15
IL158108A0 (en) 2004-03-28
CY1105318T1 (el) 2010-03-03
SA00210487B1 (ar) 2006-09-10
DE60018081D1 (de) 2005-03-17
EE04955B1 (et) 2008-02-15
UY26303A1 (es) 2001-03-16
KR100828748B1 (ko) 2008-05-09
CA2380951A1 (en) 2001-02-22
DE60018081T2 (de) 2006-01-05
RU2279894C2 (ru) 2006-07-20
EP1210119B1 (en) 2005-02-09
CA2380951C (en) 2010-03-23
KR20020059367A (ko) 2002-07-12
UA72539C2 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
PE20010636A1 (es) Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica
WO2008006076A3 (en) Alkyl lactyllactates and processes of making the same
CA2567575A1 (en) Organo-gel formulations for therapeutic applications
TR200102861T2 (tr) Uzun zincirli trigliseridler ve lipofilik surfaktantları içeren oral farmasötik kompozisyonlar.
RU2007120070A (ru) Фармацевтические и ветеринарные пастообразные композиции
UY27320A1 (es) Nuevas composiciones farmacéuticas
SG156624A1 (en) Organo-gel formulations for therapeutic applications
PE20001499A1 (es) Composiciones farmaceuticas de n-benzoil-estaurosporina
PE20030742A1 (es) Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
AR017801A1 (es) Una composicion de preconcentrado en microemulsion que contiene ciclosporina, y una formulacion farmaceutica que la comprende
RU2008138056A (ru) Композиции, пригодные для отбеливания зубов
JP2007516185A5 (es)
ES2061460T3 (es) Un composicion detergente liquida.
JP2005118776A5 (es)
BR112015013689A2 (pt) composições fluidas de cuidado oral contendo peróxido
RU2002106825A (ru) Фармацевтические композиции для перорального и местного применения
JP4429053B2 (ja) 油性洗浄料
HUP0101302A2 (hu) Szilárd tisztálkodószer és hatásjavító forgácskompozíció
JP2009149626A (ja) 皮膚バリア機能改善剤、及びそれを利用した外用剤組成物
AR014486A1 (es) UNA BARRA SoLIDA PARA LA LIMPIEZA DE LA PIEL Y UNA COMPOSICIoN ADYUVANTE EN ESCAMAS UTILIZABLE EN LA FABRICACIoN DE DICHA BARRA.
EE200200368A (et) Tramadoolvesinikkloriidi sisaldav toimeainet reguleeritult vabastav ravimkoostis ja meetod selle valmistamiseks
JP4298866B2 (ja) 脱塩素剤
RU2015122461A (ru) Композиции для ухода за полостью рта
JP2010001218A (ja) 皮膚外用組成物および皮膚再生促進剤
JPH09175936A (ja) クレンジング用組成物

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed